Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Vistagen Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTGN | Benzinga

Q: What sector and industry does Vistagen Therapeutics (VTGN) operate in?

Vistagen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Explore Vistagen Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VTGN.

Open	-
Close	-
Volume / Avg.	37.00 / 132.61K
Day Range	- - -
52 Wk Range	1.90 - 4.21
Market Cap	$68.40M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	53
Short Interest	2.73%
Days to Cover	2.67

Recent News

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Zacks

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other

Vandana Singh

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	37.00 / 132.61K
Day Range	- - -
52 Wk Range	1.90 - 4.21
Market Cap	$68.40M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	53
Short Interest	2.73%
Days to Cover	2.67

About Vistagen Therapeutics Inc.

Sector

Health Care

Industry

Biotechnology

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceut...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Vistagen Therapeutics (VTGN) stock?

You can purchase shares of Vistagen Therapeutics (NASDAQ:VTGN) through any online brokerage.

View our list of the best stock brokerages

Who are Vistagen Therapeutics (VTGN) competitors?

Other companies in Vistagen Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Outlook Therapeutics (NASDAQ:OTLK), Skye Bioscience (NASDAQ:SKYE), OncoCyte (NASDAQ:OCX) and Armata Pharmaceuticals (AMEX:ARMP).

What is the forecast, or price target, for Vistagen Therapeutics (VTGN) stock?

Vistagen Therapeutics has a consensus price target of $19.00.

What is the current price for Vistagen Therapeutics (VTGN)?

The stock price for Vistagen Therapeutics (NASDAQ: VTGN) is $2.37 last updated June 16, 2025 at 7:41 PM EDT.

Does Vistagen Therapeutics (VTGN) pay a dividend?

There are no upcoming dividends for Vistagen Therapeutics.

When is Vistagen Therapeutics (NASDAQ:VTGN) reporting earnings?

Vistagen Therapeutics’s Q1 earnings are confirmed for Tuesday, August 12, 2025.

Is Vistagen Therapeutics (VTGN) going to split?

There is no upcoming split for Vistagen Therapeutics.

What sector and industry does Vistagen Therapeutics (VTGN) operate in?

Vistagen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Vistagen Therapeutics Stock Price, Quotes and Forecasts

Vistagen Therapeutics (VTGN) Forecast